Prevalence of metabolic syndrome in beta-thalassemia major adult patients in Tanta University Hospitals

Introduction: one of long-term complications of Beta-thalassemia major (β-TM) disease is metabolic syndrome, which has a significant influence on patients' quality of life. Objective: to investigate the prevalence of metabolic syndrome in β-thalassemia major patients in Tanta University Hospitals. Materials and methods: our study included two groups. Group I: consist of (100) adult beta-thalassemia major patients. Group II: consist of (100) sex and age matched healthy subjects as control group.  Results: the present study revealed that 29% of our β-thalassemia major patients had metabolic syndrome while in control group it was 2.0%, and low high-density lipoprotein (HDL)was the most frequent positive criterion it was 86.0% in β-thalassemia major patients' group. Prevalence of hyperglycemia, abdominal obesity, hypertriglyceridemia, and hypertension in patients with thalassemia was 29, 41, 21and 7%, respectively. Prevalence of metabolic syndrome in female patient was 34.3% while in male beta thalassemia major patient it was 18.2%. the prevalence of metabolic syndrome in well chelated beta thalassemia major patient was 0.0%, while in poorly chelated patients it was 35.4%. Conclusions: this study revealed that 29% of β-thalassemia major group patients had International Diabetes Federation (IDF) criteria of metabolic syndrome and low HDL was the most frequent positive criterion. 

[1]  O. Rakhmonov,et al.  Results of endoscopic treatment of benign prostatic hyperplasia in patients with metabolic syndrome , 2021, International journal of health & medical sciences.

[2]  Wayan Suryasa,et al.  Health and treatment of diabetes mellitus , 2021, International journal of health sciences.

[3]  M. Cappellini,et al.  β-Thalassemias. , 2021, The New England journal of medicine.

[4]  V. Pinto,et al.  Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series , 2020, International journal of molecular sciences.

[5]  H. Ayyash,et al.  Hematological and biochemical evaluation of β-thalassemia major (βTM) patients in Gaza Strip: A cross-sectional study , 2018, International journal of health sciences.

[6]  G. Omrani,et al.  Prevalence of metabolic syndrome in beta thalassemia major adolescents in southern Iran: a cross-sectional study , 2018, International Journal of Diabetes in Developing Countries.

[7]  A. Farag,et al.  Metabolic syndrome in Iraqi female patients with major β-thalassemia , 2017 .

[8]  K. Yamagishi,et al.  The criteria for metabolic syndrome and the national health screening and education system in Japan , 2017, Epidemiology and health.

[9]  M. Gozashti,et al.  Prevalence of metabolic syndrome in patients with minor beta thalassemia and its related factors: a cross-sectional study , 2014, Journal of Diabetes & Metabolic Disorders.

[10]  K. Bhat,et al.  Effect of Long-Term Transfusion Therapy on the Glycometabolic Status and Pancreatic Beta Cell Function in Patients with Beta Thalassemia Major , 2014, Journal of family medicine and primary care.

[11]  D. Niederseer,et al.  Iron homeostasis in the Metabolic Syndrome , 2013, European journal of clinical investigation.

[12]  M. Monajemzadeh,et al.  Evaluation of Serum Insulin, Glucose, Lipid Profile, and Liver Function in β-Thalassemia Major Patients and Their Correlation With Iron Overload , 2010 .

[13]  E. Vichinsky,et al.  Pulmonary hypertension in thalassemia , 2010, Annals of the New York Academy of Sciences.

[14]  B. Pégourié,et al.  Complications and treatment of patients with β-thalassemia in France: results of the National Registry , 2010, Haematologica.

[15]  H. Tamary,et al.  Hypocholesterolemia in chronic anemias with increased erythropoietic activity , 2007, American journal of hematology.

[16]  M. Campbell,et al.  Health and Quality of Life Outcomes , 2006 .

[17]  J. Suvarna,et al.  Insulin resistance and beta cell function in chronically transfused patients of thalassemia major. , 2006, Indian pediatrics.

[18]  A. Asadi-Pooya,et al.  Body mass index in children with beta-thalassemia major. , 2004, Turkish journal of haematology : official journal of Turkish Society of Haematology.

[19]  A. Khalifa,et al.  Abnormal glucose tolerance in Egyptian beta‐thalassemic patients: possible association with genotyping , 2004, Pediatric diabetes.

[20]  D. Weatherall,et al.  2003 William Allan Award address. The Thalassemias: the role of molecular genetics in an evolving global health problem. , 2004, American journal of human genetics.

[21]  A. El‐Beshlawy,et al.  Thalassemia Prevalence and Status in Egypt , 1999, Pediatric Research.

[22]  X. Luo,et al.  Diabetic Nephropathy in Hypertransfused Patients With β-Thalassemia: The role of oxidative stress , 1998, Diabetes Care.

[23]  M. Maioli,et al.  Plasma lipoprotein composition, apolipoprotein(a) concentration and isoforms in beta-thalassemia. , 1997, Atherosclerosis.

[24]  J. Delhanty,et al.  Identification of novel Asian Indian and Japanese mutations causing β-thalassaemia in the Egyptian population , 1997, Human Genetics.

[25]  G. Brittenham,et al.  Iron-chelating therapy and the treatment of thalassemia. , 1997, Blood.